Sign in →

Test Code EZNT8 Zinc Transporter 8 (ZnT8) Antibody, Serum

Reporting Name

ZnT8 Ab, S

Useful For

Clinical distinction of type 1 from type 2 diabetes mellitus

 

Identification of individuals at risk of type 1 diabetes (including high-risk relatives of patients with diabetes, and those with gestational diabetes)

 

Prediction of future need for insulin treatment in adult-onset diabetic patients

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum


Specimen Required


Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Specimen Volume: 2 mL


Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 28 days
  Frozen  28 days
  Ambient  72 hours

Reference Values

<15.0 U/mL

Day(s) Performed

Tuesday, Thursday

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86341

LOINC Code Information

Test ID Test Order Name Order LOINC Value
EZNT8 ZnT8 Ab, S 76651-9

 

Result ID Test Result Name Result LOINC Value
64926 ZnT8 Ab, S 76651-9

Clinical Reference

1. Bingley PJ: Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab 2010;95:25-33

2. Andersson C, Vaziri-Sani F, Delli A, et al: Triple specificity of ZnT8 autoantibodies in relation to HLA and other islet autoantibodies in childhood and adolescent type 1 diabetes. Pediatr Diabetes 2013;14:97-105

3. Dereke J, Nilsson C, Landin-Olsson M, Hillman M: Prevalence of zinc transporter 8 antibodies in gestational diabetes mellitus. Diabet Med 2012;29:e436-439

4. Gorus FK, Balti EV, Vermeulen I, et al: Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients. Clin Exp Immunol 2013;171:82-90

5. Petruzelkova L, Ananieva-Jordanova R, Vcelakova J, et al:  The dynamic changes of zinc transporter 8 autoantibodies in Czech children from the onset of Type 1 diabetes mellitus. Diabet Med 2014;31:165-171

Method Description

Zinc Transporter 8 (ZnT8) antibodies are principally directed against the C terminal domain of ZnT8. The ZnT8 autoantibody ELISA is based on the bridging principle that employs the ability of divalent ZnT8 autoantibodies to bind to ZnT8 coated on to the plate well with one arm, and to liquid ZnT8-biotin with the other arm. Calibrators or undiluted serum samples in duplicate are added to ZnT- coated plate wells and incubated overnight. ZnT8-biotin is added to each well and plate. After another incubation, aspiration, and wash, streptavidin-peroxidase is added to each well. Another incubation, aspiration, and wash are performed and peroxidase substrate is added. After a final incubation, 0.5 mol/L H2S04 stop solution is added to each well. Absorbance is measured at 450 nm, blanked against wells containing peroxidase substrate and H2S04 only.

Report Available

3 to 7 days

Reject Due To

Gross hemolysis OK
Gross lipemia OK
Gross icterus OK

Method Name

Enzyme-Linked Immunosorbent Assay (ELISA)

Secondary ID

64926